Enliven Therapeutics

Enliven Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for cancer. The company’s current pipeline centers on precision oncology programs designed to target clinically validated pathways with greater selectivity and improved tolerability. Its lead candidates include ELVN-001, a kinase inhibitor being evaluated for chronic myeloid leukemia, and ELVN-002, a CNS-penetrant HER2 inhibitor being studied in HER2-altered solid tumors such as non-small cell lung cancer. Enliven Therapeutics, Inc. operates in the oncology drug development market, where small molecule inhibitors play an important role in addressing unmet needs across liquid and solid tumors. The company is headquartered in Boulder, Colorado, and is organized around research and early-stage clinical development of targeted cancer therapies.